# Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

> **NCT01863459** · PHASE4 · COMPLETED · sponsor: **Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada** · enrollment: 42 (actual)

## Conditions studied

- Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders

## Interventions

- **DRUG:** Lisdexamfetamine Dimesylate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01863459
- **Lead sponsor:** Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863459, "Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01863459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*